• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将端粒维持和调控与神经母细胞瘤肿瘤细胞的发育起源和分化状态联系起来。

Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells.

机构信息

Department of Microbiology & Immunology, W. R. Hearst Microbiology Research Center, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, USA.

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

出版信息

J Hematol Oncol. 2022 Aug 27;15(1):117. doi: 10.1186/s13045-022-01337-w.

DOI:10.1186/s13045-022-01337-w
PMID:36030273
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9420296/
Abstract

A cardinal feature that distinguishes clinically high-risk neuroblastoma from low-risk tumors is telomere maintenance. Specifically, neuroblastoma tumors with either active telomerase or alternative lengthening of telomeres exhibit aggressive growth characteristics that lead to poor outcomes, whereas tumors without telomere maintenance can be managed with observation or minimal treatment. Even though the need for cancer cells to maintain telomere DNA-in order to sustain cell proliferation-is well established, recent studies suggest that the neural crest origin of neuroblastoma may enforce unique relationships between telomeres and tumor malignancy. Specifically in neuroblastoma, telomere structure and telomerase activity are correlated with the adrenergic/mesenchymal differentiation states, and manipulating telomerase activity can trigger tumor cell differentiation. Both findings may reflect features of normal neural crest development. This review summarizes recent advances in the characterization of telomere structure and telomere maintenance mechanisms in neuroblastoma and discusses the findings in the context of relevant literature on telomeres during embryonic and neural development. Understanding the canonical and non-canonical roles of telomere maintenance in neuroblastoma could reveal vulnerabilities for telomere-directed therapies with potential applications to other pediatric malignancies.

摘要

一个区分临床高危神经母细胞瘤与低危肿瘤的关键特征是端粒维持。具体来说,具有活性端粒酶或端粒的替代性延长的神经母细胞瘤肿瘤表现出侵袭性生长特征,导致不良结局,而没有端粒维持的肿瘤可以通过观察或最小化治疗来管理。尽管癌细胞需要维持端粒 DNA 以维持细胞增殖是明确的,但最近的研究表明,神经母细胞瘤的神经嵴起源可能在端粒和肿瘤恶性之间施加独特的关系。具体在神经母细胞瘤中,端粒结构和端粒酶活性与肾上腺素能/间充质分化状态相关,并且操纵端粒酶活性可以触发肿瘤细胞分化。这两个发现都可能反映了正常神经嵴发育的特征。这篇综述总结了神经母细胞瘤中端粒结构和端粒维持机制的特征描述方面的最新进展,并讨论了在胚胎和神经发育过程中端粒相关文献背景下的发现。了解端粒维持在神经母细胞瘤中的规范和非规范作用可能揭示针对端粒的治疗方法的脆弱性,这些方法可能适用于其他儿科恶性肿瘤。

相似文献

1
Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells.将端粒维持和调控与神经母细胞瘤肿瘤细胞的发育起源和分化状态联系起来。
J Hematol Oncol. 2022 Aug 27;15(1):117. doi: 10.1186/s13045-022-01337-w.
2
Reciprocal impacts of telomerase activity and ADRN/MES differentiation state in neuroblastoma tumor biology.端粒酶活性和 ADRN/MES 分化状态在神经母细胞瘤肿瘤生物学中的相互影响。
Commun Biol. 2021 Nov 19;4(1):1315. doi: 10.1038/s42003-021-02821-8.
3
Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.端粒修剪和 DNA 损伤作为高危神经母细胞瘤的特征。
Neoplasia. 2019 Jul;21(7):689-701. doi: 10.1016/j.neo.2019.04.002. Epub 2019 May 23.
4
How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?端粒异常如何调节神经母细胞瘤的生物学特性?
Biomolecules. 2021 Jul 28;11(8):1112. doi: 10.3390/biom11081112.
5
Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.针对高危神经母细胞瘤中端粒维持机制的新型治疗策略。
J Exp Clin Cancer Res. 2020 May 6;39(1):78. doi: 10.1186/s13046-020-01582-2.
6
Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.端粒维持机制定义高危神经母细胞瘤的临床转归。
Cancer Res. 2020 Jun 15;80(12):2663-2675. doi: 10.1158/0008-5472.CAN-19-3068. Epub 2020 Apr 14.
7
Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).端粒长度在癌症中的维持:端粒酶与端粒的非酶延长(ALT)的十字路口。
Int J Mol Sci. 2018 Feb 18;19(2):606. doi: 10.3390/ijms19020606.
8
Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.神经母细胞瘤中的端粒生物学:端粒结合蛋白和端粒的替代强化。
J Pediatr Surg. 2009 Dec;44(12):2258-66. doi: 10.1016/j.jpedsurg.2009.07.046.
9
Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.神经肿瘤起始细胞具有独特的端粒维持能力,可安全地靶向端粒酶抑制。
Clin Cancer Res. 2011 Jan 1;17(1):111-21. doi: 10.1158/1078-0432.CCR-10-2075.
10
Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.端粒延长的替代机制:许可性突变、DNA 修复蛋白和致瘤进展。
Mutat Res. 2013 Mar-Apr;743-744:142-150. doi: 10.1016/j.mrfmmm.2012.11.006. Epub 2012 Dec 3.

引用本文的文献

1
Clinical Significance of Promoter Mutations in Neuroblastoma.神经母细胞瘤中启动子突变的临床意义
JCO Precis Oncol. 2025 Jul;9:e2500074. doi: 10.1200/PO-25-00074. Epub 2025 Jul 10.
2
Regulatory roles of insulin growth factor binding protein family in neuroblastoma cell proliferation and differentiation: Potential prognostic biomarkers and therapeutic targets for neuroblastoma.胰岛素生长因子结合蛋白家族在神经母细胞瘤细胞增殖和分化中的调控作用:神经母细胞瘤潜在的预后生物标志物和治疗靶点
Pediatr Discov. 2024 Jun 8;2(3):e68. doi: 10.1002/pdi3.68. eCollection 2024 Sep.
3
Interplay Between the Epigenome, the Microenvironment, and the Immune System in Neuroblastoma.

本文引用的文献

1
The non-telomeric evolutionary trajectory of TRF2 in zebrafish reveals its specific roles in neurodevelopment and aging.斑马鱼中 TRF2 的非端粒进化轨迹揭示了其在神经发育和衰老中的特定作用。
Nucleic Acids Res. 2022 Feb 28;50(4):2081-2095. doi: 10.1093/nar/gkac065.
2
Epigenetic state determines inflammatory sensing in neuroblastoma.表观遗传学状态决定神经母细胞瘤中的炎症感应。
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6). doi: 10.1073/pnas.2102358119.
3
Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.
神经母细胞瘤中表观基因组、微环境与免疫系统之间的相互作用
Cancers (Basel). 2025 May 29;17(11):1812. doi: 10.3390/cancers17111812.
4
Identification of telomere maintenance-driven molecular subtypes in hepatocellular carcinoma: implications for prognosis and targeted therapy via KPNA2.肝细胞癌中端粒维持驱动分子亚型的鉴定:通过核转运蛋白α2对预后和靶向治疗的意义
Discov Oncol. 2025 Apr 11;16(1):516. doi: 10.1007/s12672-025-02311-x.
5
Peripheral neuroblastic tumors behaving badly: an update on high-risk morphologic and molecular groupings.行为不良的外周神经母细胞瘤:高危形态学和分子分组的最新进展
Virchows Arch. 2025 May;486(5):895-903. doi: 10.1007/s00428-025-04083-9. Epub 2025 Mar 29.
6
Tackling ALT-positive neuroblastoma: is it time to redefine risk classification systems? A systematic review with IPD meta-analysis.应对ALT阳性神经母细胞瘤:是时候重新定义风险分类系统了吗?一项基于个体患者数据荟萃分析的系统评价
Neoplasia. 2025 Feb;60:101106. doi: 10.1016/j.neo.2024.101106. Epub 2024 Dec 28.
7
The mechanism of NF-κB-TERT feedback regulation of granulosa cell apoptosis in PCOS rats.多囊卵巢综合征大鼠中 NF-κB-TERT 反馈调节颗粒细胞凋亡的机制。
PLoS One. 2024 Oct 25;19(10):e0312115. doi: 10.1371/journal.pone.0312115. eCollection 2024.
8
Long Non-Coding RNAs in Neuroblastoma: Pathogenesis, Biomarkers and Therapeutic Targets.长链非编码 RNA 在神经母细胞瘤中的作用:发病机制、生物标志物和治疗靶点。
Int J Mol Sci. 2024 May 23;25(11):5690. doi: 10.3390/ijms25115690.
9
Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity.枪中两弹:通过靶向肾上腺素能-间充质可塑性,将免疫疗法与化疗相结合以战胜神经母细胞瘤。
Front Immunol. 2023 Oct 2;14:1268645. doi: 10.3389/fimmu.2023.1268645. eCollection 2023.
10
Long-Term Survival of Neuroblastoma Patients Receiving Surgery, Chemotherapy, and Radiotherapy: A Propensity Score Matching Study.接受手术、化疗和放疗的神经母细胞瘤患者的长期生存:一项倾向评分匹配研究
J Clin Med. 2023 Jan 17;12(3):754. doi: 10.3390/jcm12030754.
端粒酶是神经母细胞瘤预后不良的一个预后标志物及治疗靶点。
JCO Precis Oncol. 2019 Dec;3:1-20. doi: 10.1200/PO.19.00072.
4
Reciprocal impacts of telomerase activity and ADRN/MES differentiation state in neuroblastoma tumor biology.端粒酶活性和 ADRN/MES 分化状态在神经母细胞瘤肿瘤生物学中的相互影响。
Commun Biol. 2021 Nov 19;4(1):1315. doi: 10.1038/s42003-021-02821-8.
5
The evolution of metazoan shelterin.后生动物庇护素的进化。
Genes Dev. 2021 Dec 1;35(23-24):1625-1641. doi: 10.1101/gad.348835.121. Epub 2021 Nov 11.
6
Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma.p53缺失可抑制ATRX缺陷型神经母细胞瘤中复制应激诱导的DNA损伤。
Oncogenesis. 2021 Nov 6;10(11):73. doi: 10.1038/s41389-021-00363-6.
7
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.修正的神经母细胞瘤风险分类系统:来自儿童肿瘤协作组的报告。
J Clin Oncol. 2021 Oct 10;39(29):3229-3241. doi: 10.1200/JCO.21.00278. Epub 2021 Jul 28.
8
Mutational signatures: emerging concepts, caveats and clinical applications.突变特征:新兴概念、注意事项与临床应用
Nat Rev Cancer. 2021 Oct;21(10):619-637. doi: 10.1038/s41568-021-00377-7. Epub 2021 Jul 27.
9
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage.一项系统性的CRISPR筛选确定了复制错误和内源性DNA损伤所导致的特征背后的突变机制。
Nat Cancer. 2021 Jun;2(6):643-657. doi: 10.1038/s43018-021-00200-0. Epub 2021 Apr 26.
10
Molecular Genetics in Neuroblastoma Prognosis.神经母细胞瘤预后中的分子遗传学
Children (Basel). 2021 May 29;8(6):456. doi: 10.3390/children8060456.